ArticleFrontiers in public health2025
Long-term symptom burden in a young, ambulatory cohort after the omicron outbreak in China.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: At the end of 2022, an outbreak of the Omicron BF.7 and BA.5.2 subvariants of SARS-CoV-2 occurred in China. In this prospective cohort study, we investigated the pattern of development of major symptom burden and influencing factors in infected Chinese patients. Methods: First-time infected outpatients were enrolled from December 7, 2022, to January 11, 2023 ( Results: At the onset of the infection, the most prevalent symptoms (score ≥1 on a 0-10 numeric rating scale) were fatigue (91.8%), cough (91.8%), and sore throat (91.5%) among 33 symptoms monitored. Patients with higher scores for symptom Cluster II (lack of appetite, disturbed sleep, shivering, drowsiness, sweating, nausea, depression, and anxiety) and symptom cluster V (fatigue, sore throat, dry mouth, and dizziness) reported poorer quality of life than other patients during the first month after enrolment. The most severe symptoms (score≥7) lasted during 3-9 months were depression (5.2%), fatigue (4.8%), anxiety (4.8%), runny nose (4.3%), muscle or joint pain (3.3%), nasal congestion (3.0%), disturbed sleep(2.6%). Younger age, female sex, and body mass index of at least 24 kg/m Conclusion: This cohort study identified patterns and characteristics of symptom evolution in outpatients at 9 months post-COVID-19 diagnosis and provides targets for long-term care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.